Free Trial
NASDAQ:AVTE

Aerovate Therapeutics (AVTE) Stock Price, News & Analysis

$1.45
-0.05 (-3.33%)
(As of 06/25/2024 ET)
Today's Range
$1.44
$1.51
50-Day Range
$1.41
$24.62
52-Week Range
$1.25
$32.42
Volume
1.16 million shs
Average Volume
523,622 shs
Market Capitalization
$41.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.25

Aerovate Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
54.6% Upside
$2.25 Price Target
Short Interest
Bearish
11.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.73mentions of Aerovate Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$2.70 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.87) to ($1.15) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.23 out of 5 stars

Medical Sector

466th out of 890 stocks

Pharmaceutical Preparations Industry

214th out of 427 stocks

AVTE stock logo

About Aerovate Therapeutics Stock (NASDAQ:AVTE)

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

AVTE Stock Price History

AVTE Stock News Headlines

Wall Street legend issues dire warning about NVDA
This former Wall Street market maker is issuing a dire warning… “Millions of traders are about to make a [lin]HUGE mistake with NVDA’s stock!” And it’s all due to one of the most common misconceptions in the markets… A fundamental misunderstanding about what makes stock move! Fortunately, this Wall Street legend is standing by to show you…
Wall Street legend issues dire warning about NVDA
This former Wall Street market maker is issuing a dire warning… “Millions of traders are about to make a [lin]HUGE mistake with NVDA’s stock!” And it’s all due to one of the most common misconceptions in the markets… A fundamental misunderstanding about what makes stock move! Fortunately, this Wall Street legend is standing by to show you…
See More Headlines
Receive AVTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/13/2024
Today
6/25/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AVTE
Fax
N/A
Employees
51
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.25
High Stock Price Target
$3.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+50.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Net Income
$-75,520,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.96 per share

Miscellaneous

Free Float
21,645,000
Market Cap
$43.23 million
Optionable
Optionable
Beta
1.30
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Timothy P. Noyes M.B.A. (Age 62)
    CEO & Director
    Comp: $936.9k
  • Mr. George A. Eldridge (Age 61)
    CFO & Treasurer
    Comp: $658.6k
  • Mr. Timothy J. Pigot (Age 53)
    Chief Commercial Officer
    Comp: $584.6k
  • Dr. Benjamin T. Dake Ph.D. (Age 48)
    Founder, President, COO & Secretary
    Comp: $435.5k
  • Dr. Marinus Verwijs Ph.D. (Age 48)
    Chief Technical Officer
    Comp: $439.88k
  • Dr. Ralph W. Niven M.B.A. (Age 64)
    M.R, Ph.D., Pharm.S, Chief Scientific Officer
    Comp: $372.33k
  • Mr. Hunter Gillies M.D. (Age 58)
    Chief Medical Officer
    Comp: $512.74k
  • Ms. Donna Dea
    Head of Regulatory Affairs
  • Ms. Susan Fischer
    Executive Vice President of Development Operations
  • Mr. Stephen K. Yu
    Senior Vice President of Quality

AVTE Stock Analysis - Frequently Asked Questions

Should I buy or sell Aerovate Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aerovate Therapeutics in the last twelve months. There are currently 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AVTE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVTE, but not buy additional shares or sell existing shares.
View AVTE analyst ratings
or view top-rated stocks.

What is Aerovate Therapeutics' stock price target for 2024?

6 brokers have issued twelve-month price objectives for Aerovate Therapeutics' shares. Their AVTE share price targets range from $2.00 to $3.00. On average, they predict the company's share price to reach $2.25 in the next year. This suggests a possible upside of 54.6% from the stock's current price.
View analysts price targets for AVTE
or view top-rated stocks among Wall Street analysts.

How have AVTE shares performed in 2024?

Aerovate Therapeutics' stock was trading at $22.63 at the start of the year. Since then, AVTE stock has decreased by 93.6% and is now trading at $1.4550.
View the best growth stocks for 2024 here
.

When is Aerovate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our AVTE earnings forecast
.

How were Aerovate Therapeutics' earnings last quarter?

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) posted its quarterly earnings data on Monday, May, 13th. The company reported ($0.83) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.09.

When did Aerovate Therapeutics IPO?

Aerovate Therapeutics (AVTE) raised $100 million in an initial public offering on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share.

Who are Aerovate Therapeutics' major shareholders?

Aerovate Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.41%), Ikarian Capital LLC (1.28%), EntryPoint Capital LLC (0.01%) and California State Teachers Retirement System (0.00%). Insiders that own company stock include Benjamin T Dake, Cormorant Asset Management, Lp, David S Grayzel, George A Eldridge, Hunter Gillies, Marinus Verwijs, Ralph Niven and Timothy P Noyes.
View institutional ownership trends
.

How do I buy shares of Aerovate Therapeutics?

Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVTE) was last updated on 6/25/2024 by MarketBeat.com Staff

From Our Partners